A Multicenter Randomized Double-Blind Placebo-Controlled Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy

Brief description of study

Immunoglobulin A nephropathy is a chronic disease with periodic flares. There are currently no approved therapies for IgAN, and the current treatment strategies consist of 2 main approaches: nonspecific supportive treatments consisting of BP control, treatment with ACEI/ARB, smoking cessation, lipid reduction, low-salt diet, or fish oil, and immunosuppressive therapies such as steroids, cyclophosphamide, or azathioprine. The purpose of this study is to find out about the safety and efficacy of VIS649 over a 12-month treatment course in participants with Immunoglobulin A (IgA) Nephropathy (IgAN). VIS649 is an experimental drug which is not approved by Health Authorities including United states (U.S.) Food and Drug Administration (FDA) for the treatment of IgAN.


Clinical Study Identifier: s19-01930
ClinicalTrials.gov Identifier: NCT04287985
Principal Investigator: Olga Zhdanova.
Other Investigator: Safa M. Kalache.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.